Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens
Goffin, J. R., Nicholas, G., Mates, M., Tu, D., Chen, E., Laurie, S. A., Juergens, R., Robinson, A., Goss, G., Reaume, M., Sun, S., Christink, K., Maize, C., MacFarlan, S., Sun, X., Ritter, H., Seymour, L., Bradbury, P. A.
Published in Investigational new drugs (01.06.2019)
Published in Investigational new drugs (01.06.2019)
Get full text
Journal Article